OLN OLIN Corp
Chemicals & Allied Products · NYSE · SEC CIK 74303 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.7%
TTM net income YoY-531.2%
TTM EPS YoY-519.1%
Revenue 3-yr CAGR-2.2%
Net income 3-yr CAGR—
Margins
Gross margin6.7%
Operating margin-1.9%
Net margin-3.3%
FCF margin3.3%
EBITDA margin5.2%
Returns
ROE-12.2%
ROA-3.0%
ROIC (approx.)-2.2%
Asset turnover0.90x
Leverage & solvency
Liabilities / assets76.8%
Debt / equity1.75x
Current ratio1.45x
Interest coverage-0.71x
Cash quality & payout
Operating cash flow / net income-1.74x
Accruals ratio-8.2%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6.78B | $6.54B |
| Cost of revenue | $6.28B | $5.80B |
| Gross profit | $501.50M | $737.50M |
| SG&A expense | $463.30M | $408.50M |
| Operating income | $5.30M | $296.50M |
| Interest expense | $188.30M | $184.50M |
| Pretax income | -$161.10M | $141.70M |
| Income tax | -$60.00M | $36.70M |
| Net income | -$101.10M | $105.00M |
| EBITDA | $526.90M | $814.60M |
| EPS (basic) | -0.88 | 0.92 |
| EPS (diluted) | -0.88 | 0.91 |
| Weighted avg. shares (diluted) | 114.60M | 119.50M |
| Balance sheet | ||
| Cash & equivalents | $167.60M | $175.60M |
| Short-term investments | $0 | $0 |
| Inventory | $784.50M | $823.50M |
| Current assets | $1.97B | $2.08B |
| PP&E, net | $2.20B | $2.33B |
| Goodwill | $1.43B | $1.42B |
| Intangibles | $174.40M | $206.60M |
| Total assets | $7.33B | $7.58B |
| Current liabilities | $1.63B | $1.63B |
| Short-term debt | $109.70M | $129.00M |
| Long-term debt | $2.72B | $2.71B |
| Total debt | $2.83B | $2.84B |
| Total liabilities | $5.46B | $5.52B |
| Shareholders' equity | $1.84B | $2.02B |
| Net debt | $2.66B | $2.67B |
| Shares outstanding | 113.60M | 115.70M |
| Cash flow statement | ||
| Operating cash flow | $474.20M | $503.20M |
| Capital expenditure | $226.30M | $195.10M |
| Free cash flow | $247.90M | $308.10M |
| Investing cash flow | -$319.60M | -$283.70M |
| Financing cash flow | -$163.00M | -$212.60M |
| Depreciation & amortization | $521.60M | $518.10M |
| Stock-based compensation | $20.70M | $17.10M |
| Dividends paid | $91.60M | $94.20M |
| Share buybacks | $50.50M | $300.30M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.